Abstract
Nucleic Acid Based Drugs (NABDs) constitute a class of promising and powerful therapeutic new agents with limited side effects, potentially useable against a wide range of diseases, including cancer. Among them, the short interfering RNAs (siRNAs), represent very effective molecules. Despite their in vitro efficacy, the major drawback that limits siRNAs usage consists in a difficult delivery due to their very low stability in physiological fluids, and to their limited membrane-permeability through physiological barriers. On the other hand, the liposomes (lipid bilayers closed in vesicles of various sizes) represent interesting drug delivery systems (DDSs) which can be tailored in order to get the best performance in terms of load, vesicle size and transfection yield. In this work, the current state of study in these two fields, and the connections between them, are briefly summarized.
Keywords: Drug delivery, encapsulating methods, liposomes, nucleic acid based drugs (NABDs), polymeric carriers, small interfering RNAs (siRNAs).
Current Drug Metabolism
Title:Liposomes as siRNA Delivery Vectors
Volume: 15 Issue: 9
Author(s): Sabrina Bochicchio, Annalisa Dalmoro, Anna Angela Barba, Gabriele Grassi and Gaetano Lamberti
Affiliation:
Keywords: Drug delivery, encapsulating methods, liposomes, nucleic acid based drugs (NABDs), polymeric carriers, small interfering RNAs (siRNAs).
Abstract: Nucleic Acid Based Drugs (NABDs) constitute a class of promising and powerful therapeutic new agents with limited side effects, potentially useable against a wide range of diseases, including cancer. Among them, the short interfering RNAs (siRNAs), represent very effective molecules. Despite their in vitro efficacy, the major drawback that limits siRNAs usage consists in a difficult delivery due to their very low stability in physiological fluids, and to their limited membrane-permeability through physiological barriers. On the other hand, the liposomes (lipid bilayers closed in vesicles of various sizes) represent interesting drug delivery systems (DDSs) which can be tailored in order to get the best performance in terms of load, vesicle size and transfection yield. In this work, the current state of study in these two fields, and the connections between them, are briefly summarized.
Export Options
About this article
Cite this article as:
Bochicchio Sabrina, Dalmoro Annalisa, Barba Angela Anna, Grassi Gabriele and Lamberti Gaetano, Liposomes as siRNA Delivery Vectors, Current Drug Metabolism 2014; 15 (9) . https://dx.doi.org/10.2174/1389200216666150206124913
DOI https://dx.doi.org/10.2174/1389200216666150206124913 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemotherapy-Induced Modifications to Gastrointestinal Microflora: Evidence and Implications of Change
Current Drug Metabolism Technetium-99m-based Radiopharmaceuticals in Sentinel Lymph Node Biopsy: Gynecologic Oncology Perspective
Current Pharmaceutical Design Angiogenesis-Related Cytokines in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials Kinase Phosphorylation-based Mechanisms of PARP Inhibitor Resistance During Synthetic Lethal Oncotherapy
Current Signal Transduction Therapy Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer
Current Drug Targets Editorial
Current Medical Imaging Safety of Cabergoline in the Management of Pituitary Prolactin-Induced Symptoms with Patients Treated with Atypical Neuroleptics
Current Drug Safety Computational and Synthetic Biology Approaches for the Biosynthesis of Antiviral and Anticancer Terpenoids from <i>Bacillus subtilis</i>
Medicinal Chemistry Synthesis, Structure-Activity Relationships and Antagonistic Effects in Human MCF-7 Breast Cancer Cells of Flexible Estrogen Receptor Modulators
Medicinal Chemistry Cigarette Smoking, Metabolic Activation and Carcinogenesis
Current Drug Metabolism Kisspeptin Mediated Signaling in Cancer
Current Topics in Medicinal Chemistry The Anti-cancer Actions of Vitamin D
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Regulators Governing Cancer Stem Cells and Epithelial- Mesenchymal Transition in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy Natural Molecules as Talented Inhibitors of Nucleotide Pyrophosphatases/ Phosphodiesterases (PDEs)
Current Topics in Medicinal Chemistry Regulation of Gene Expression by Progesterone in Cancer Cells: Effects on Cyclin D1, EGFR and VEGF
Mini-Reviews in Medicinal Chemistry Bv8-Prokineticins and their Receptors: Modulators of Pain
Current Pharmaceutical Biotechnology MIIP, a Cytoskeleton Regulator that Blocks Cell Migration and Invasion, Delays Mitosis, and Suppresses Tumorogenesis
Current Protein & Peptide Science Protein Arrays: Recent Achievements and their Application to Study the Human Proteome
Current Proteomics Patent Selections
Recent Patents on Biomedical Engineering (Discontinued)